OncoMatch/Clinical Trials/NCT06946927
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Is NCT06946927 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JMKX001899 and IN10018 for nsclc (advanced non-small cell lung cancer).
Treatment: JMKX001899 · IN10018 · Chemotherapy: Pemetrexed · Carboplatin — This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C mutation
Known KRAS G12C mutation
Required: EGFR wild-type
negative results for other driver genes with approved targeted therapies
Required: ALK wild-type
negative results for other driver genes with approved targeted therapies
Required: ROS1 wild-type
negative results for other driver genes with approved targeted therapies
Required: BRAF wild-type
negative results for other driver genes with approved targeted therapies
Required: RET wild-type
negative results for other driver genes with approved targeted therapies
Required: MET wild-type
negative results for other driver genes with approved targeted therapies
Required: NTRK1 wild-type
negative results for other driver genes with approved targeted therapies
Required: NTRK2 wild-type
negative results for other driver genes with approved targeted therapies
Required: NTRK3 wild-type
negative results for other driver genes with approved targeted therapies
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: within 4 weeks of receipt of study drug
Prior chemotherapy...within 4 weeks of receipt of study drug
Cannot have received: radiotherapy
Exception: within 4 weeks of receipt of study drug
Prior radiotherapy...within 4 weeks of receipt of study drug
Cannot have received: immunotherapy
Exception: within 4 weeks of receipt of study drug
Prior immunotherapy...within 4 weeks of receipt of study drug
Cannot have received: investigational agent
Exception: within 4 weeks of receipt of study drug
Prior treatment with an investigational agent within 4 weeks of receipt of study drug
Cannot have received: nitrosoureas
Exception: within 6 weeks of receipt of study drug
within 6 weeks for nitrosoureas
Cannot have received: mitomycin C (mitomycin C)
Exception: within 6 weeks of receipt of study drug
within 6 weeks for...mitomycin C
Cannot have received: small molecule targeted therapies
Exception: within 2 weeks of receipt of study drug
within 2 weeks of small molecule targeted therapies
Cannot have received: traditional medicine with anticancer indication
Exception: within 2 weeks of receipt of study drug
within 2 weeks of...traditional medicine with anticancer indication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06946927 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, immunotherapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS G12C mutation is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages